Generated by AI
electroCore, Inc. is a commercial-stage bioelectronic medicine company that develops non-invasive vagus nerve stimulation (nVNS) products for healthcare and wellness use. Its core offerings include gammaCore, a prescription handheld device used for primary headache conditions such as migraine and cluster headache, as well as Quell Fibromyalgia for chronic pain management. The company also markets Truvaga and TAC-STIM, consumer-focused nVNS products designed to support general wellness and human performance. electroCore’s technology platform is built around non-invasive neuromodulation, with products intended for both clinical and personal use across the United States, the United Kingdom, and international markets. Headquartered in Rockaway, New Jersey, electroCore serves a growing role in the medical device and bioelectronic therapy sectors by offering portable, non-surgical alternatives that address pain, wellness, and performance-related needs.
Website200 Forge Way
Rockaway, NJ, 07866
United States
The latest articles about ECOR.
electroCore Inc (ECOR) posted record net sales of $9.7 million and its lowest operating loss ever, while guiding for 30-40% revenue growth in 2027 and a path to positive adjusted EBITDA by year-end.
Summary of May 26's posts. Generated by AI.
Summary of Nov 13's posts. Generated by AI.
Summary of Dec 29's posts. Generated by AI.
Investors talking about ECOR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.